BC
BMY.RT

Birchview Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Birchview Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,105,313
Closed -$763K – 57
2020
Q4 		$763K Sell
1,105,313
-101,535
-8% -$216K 0.44% 33
2020
Q3 		$2.71M Buy
1,206,848
+500,000
+71% +$1.43M 1.81% 9
2020
Q2 		$2.53M Hold
706,848
– – 1.53% 10
2020
Q1 		$2.69M Buy
706,848
+7,200
+1% +$23.7K 2.38% 8
2019
Q4 		$2.11M Buy
+699,648
New +$1.82M 1.53% 7

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Birchview Capital's BMY.RT Position: Q1 2021 in Review

Birchview Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,105,313 shares — an estimated $763K sold.

Birchview Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2.71M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Birchview Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Birchview Capital sold 1,105,313 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $763K.
  • Birchview Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Birchview Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.71M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Birchview Capital's 13F filing for Q1 2021, filed 14 May 2021.